Literature DB >> 3580358

Short term cyclosporin A treatment of Behçet's disease.

A U Müftüoğlu, H Pazarli, S Yurdakul, H Yazici, B Y Ulkü, Y Tüzün, S Serdaroğlu, E Altuğ, H Bahçecioğlu, G Güngen.   

Abstract

Eleven separate three-month courses of cyclosporin A, an oral solution 10 mg/kg/day, were administered to eight patients with Behçet's disease with sight-threatening posterior uveitis. It was found to be effective in arresting the inflammatory activity in the eye as well as the mucocutaneous lesions of Behçet's disease. Improvement in visual acuity was observed within one week of starting therapy. Severe exacerbations in the ocular and mucocutaneous lesions occurred on withdrawal of the drug. At this dosage side effects included hirsutism in all women, and a slight rise of serum bilirubins in two patients and of blood urea in one patient. The latter two conditions responded rapidly to dose adjustment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3580358      PMCID: PMC1041174          DOI: 10.1136/bjo.71.5.387

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  10 in total

1.  Polyarthritis in Behcet's multiple symptom complex.

Authors:  R W STRACHAN; F W WIGZELL
Journal:  Ann Rheum Dis       Date:  1963-01       Impact factor: 19.103

2.  Summary of the Third International Conference on Behçet's Disease, Tokyo, Japan, October 23-24, 1981.

Authors:  J D O'Duffy; T Lehner; C G Barnes
Journal:  J Rheumatol       Date:  1983-02       Impact factor: 4.666

3.  The combined use of HLA-B5 and the pathergy test as diagnostic markers of Behçet's disease in Turkey.

Authors:  H Yazici; Y Tuzun; H Pazarli; B Yalcin; S Yurdakul; A Muftuoglu
Journal:  J Rheumatol       Date:  1980 Mar-Apr       Impact factor: 4.666

Review 4.  Behçet's disease. Report of twelve cases with three manifesting as papilledema.

Authors:  V V Kalbian; M T Challis
Journal:  Am J Med       Date:  1970-12       Impact factor: 4.965

5.  Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents.

Authors:  R B Nussenblatt; A G Palestine; C C Chan
Journal:  Am J Ophthalmol       Date:  1983-09       Impact factor: 5.258

6.  Cellular immune responsiveness of uveitis patients to retinal S-antigen.

Authors:  R B Nussenblatt; I Gery; E J Ballintine; W B Wacker
Journal:  Am J Ophthalmol       Date:  1980-02       Impact factor: 5.258

7.  Treatment of intraocular inflammatory disease with cyclosporin A.

Authors:  R B Nussenblatt; A G Palestine; A H Rook; I Scher; W B Wacker; I Gery
Journal:  Lancet       Date:  1983-07-30       Impact factor: 79.321

8.  Inhibition of T-cell activity by cyclosporin A.

Authors:  L Andrus; K J Lafferty
Journal:  Scand J Immunol       Date:  1981-05       Impact factor: 3.487

Review 9.  Cyclosporin A. Clinical pharmacology and therapeutic potential.

Authors:  D J White
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

10.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

  10 in total
  10 in total

1.  Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial.

Authors:  Y Ozyazgan; S Yurdakul; H Yazici; B Tüzün; A Işçimen; Y Tüzün; T Aktunç; H Pazarli; V Hamuryudan; A Müftüoğlu
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

2.  Cyclosporin in the treatment of severe chronic idiopathic uveitis.

Authors:  J de Vries; G S Baarsma; M J Zaal; T N Boen-Tan; A Rothova; H J Buitenhuis; C M Schweitzer; R J de Keizer; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1990-06       Impact factor: 4.638

Review 3.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

Review 4.  Immunosuppressive drugs and corticosteroids in the treatment of rheumatoid arthritis.

Authors:  M Arnold; L Schrieber; P Brooks
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

5.  Long-term therapy with low dose cyclosporin A in ocular Behçet's disease.

Authors:  Pinar Cakar Ozdal; Serap Ortaç; Ibrahim Taskintuna; Esin Firat
Journal:  Doc Ophthalmol       Date:  2002-11       Impact factor: 2.379

6.  Cyclosporin-A associated malignancy.

Authors:  Jonathan M Durnian; Rosalind M K Stewart; Richard Tatham; Mark Batterbury; Stephen B Kaye
Journal:  Clin Ophthalmol       Date:  2007-12

Review 7.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 8.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

9.  Cyclosporine effects on optic nerve and retinal vasculitis in Behçet's disease.

Authors:  P S Chavis; S R Antonios; K F Tabbara
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

Review 10.  A Clinical Picture of the Visual Outcome in Adamantiades-Behçet's Disease.

Authors:  Michele Figus; Chiara Posarelli; Timothy G Albert; Rosaria Talarico; Marco Nardi
Journal:  Biomed Res Int       Date:  2015-10-19       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.